FDA compounder NDC directory
Browse every current FDA compounder source row, including records that do not contain a usable NDC.
Compounder NDC directory#
Every current compounder source row is browsable, including records whose FDA source did not provide a usable product, package, or lookup NDC. Browse the unified current auxiliary catalog. · Browse the complete captured source and snapshot history.
| Establishment | FEI | Product NDC | Package NDC | Brand | Nonproprietary name | Active ingredients | Period | Normalization | Source date |
|---|---|---|---|---|---|---|---|---|---|
| BPI Labs LLC | 078627620 | 54288-848 | 54288-848-25 | Pyridoxine Hydrochloride; Tirzepatide | 40 mg/4 mL; 40 mg/4 mL | 2026-1 | valid | 2026-10-06 | |
| BPI Labs LLC | 54288-848 | 54288-848-25 | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | 40 mg/4 mL; 40 mg/4 mL | 2026-1 | valid | 2026-09-18 | |
| BPI Labs LLC | 078627620 | 54288-848 | 54288-848-25 | Tirzepatide | 40 mg/4 mL | 2025-2 | valid | 2026-10-06 | |
| BPI Labs LLC | 54288-848 | 54288-848-25 | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) | 40 mg/4 mL | 2025-2 | valid | 2026-09-18 |